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Abstract
Background: Cardiovascular disease (CVD) is a major contributor to the burden of disease and the number one
cause of death worldwide. From 1990 until today, more people died from coronary heart disease than from any
other cause. CVD is regularly treated with minimally or non-minimally invasive off- or on-pump cardiothoracic surgery
and several interventions related to the outcome of the surgical procedures have been evaluated in clinical trials, but
heterogeneity in outcome reporting hinders comparison of interventions across trials and limits the ability of research
synthesis. This problem is encountered with the introduction of core outcome sets (COSs), which should be measured
and reported, as a minimum, in all clinical trials for a specific clinical field.
Methods/design: This study protocol describes the methods used to develop a COS for all types of cardiac surgery
effectiveness trials. We aim to reach consensus on what to measure in an international three-round eDelphi exercise
involving adult patients in need or after cardiothoracic surgery, cardiothoracic surgeons, cardiologists, anaesthesiologists,
nursing staff and researchers with expertise in this particular field of medical research. Subsequently, outcome
measurement instruments (how to measure) will be determined. Recommendations on COS development given
by the Core Outcome Measures in Effectiveness Trials (COMET) Initiative and the Outcome Measures in Rheumatology
(OMERACT) Initiative were followed.
Discussion: The proposed COS aims to provide methodological guidance for future cardiothoracic surgical trials to
ensure the comparability of effects of interventions across studies and enable research synthesis. This does not imply
that primary outcomes should always and exclusively be those of the COS. However, to ensure the comparability of
results across trials, the outcomes included in this COS should be considered for inclusion besides measuring trial-specific
clinical endpoints.
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Background
Cardiovascular disease (CVD) is the number one cause
of death worldwide and therefore, the major contributor
to the burden of disease. Since 1990, more people have
died from coronary heart disease than from any other
cause. In 2008, 30 % of all global deaths (17.3 million)
were attributed to CVD [1]. Of these deaths, an esti-
mated 7.3 million were due to coronary artery disease
[2]. CVD results from blockage of the coronary arteries
by atherothrombosis, which is regularly treated with
minimally or non-minimally invasive off- or on-pump
cardiothoracic surgery.
A wide range of health interventions related to the
outcome of cardiac surgery has been evaluated in clinical
trials. At present, more than 3000 clinical trials investi-
gating CVD are listed in the International Clinical Trials
Registry Platform of the World Health Organisation [3]
involving thousands of patients and costing millions in
research funding. The results of clinical trials assessing
similar interventions are summarised in systematic re-
views and meta-analyses intending to provide the basis
for clinical practice guidelines and treatment recommen-
dations. However, it has been reported that clinical end-
points in cardiothoracic interventional research are
measured and reported inconsistently [4], limiting the
ability of research synthesis, a problem that is well
known to systematic reviewers [5]. As a consequence, a
significant number of identified matching studies are
regularly excluded from meta-analyses, reducing their
power and limiting the value of available evidence [6].
Furthermore, empirical research strongly determines
that outcome-reporting bias (defined by the Cochrane
Collaboration as “selective reporting of some outcomes
but not others, depending on the nature and direction of
the results”, Cochrane Handbook, Chapter 10, Table
10.1.a) has a significant impact on how the results of
clinical trials are reported [7], strongly influencing the
recommendations given by systematic reviewers.
This problem is encountered with the introduction of
minimum core outcome sets (COSs) for a specific clinical
field [5, 8]. A minimum COS is defined as an agreed mini-
mum set of outcomes that should be measured and re-
ported in all clinical trials for a specific clinical area [5].
COSs are intended to increase the reporting of outcomes
important to all stakeholders, limit study heterogeneity
and avoid selective reporting [8].
The Outcome Measures in Rheumatology (OMERACT)
Initiative [9] suggests a stepwise approach (Fig. 1) to COS
development and introduced a new framework, which
aims to include all key aspects of a health condition to en-
sure the comprehensiveness and applicability of COSs [9].
OMERACT Filter 2.0 (Table 1) was created to broaden
the international classification of functioning, disability
and health [10] and suggests four core domain areas: (1)
death, (2) life impact, (3) resource use and (4) patho-
physiological manifestations. By doing so, the outcome
domains and measurement instruments will be consistent
with the reporting framework currently introduced for the
US Clinical Trials Registry [11] and will completely cover
what is measurable in a clinical trial comprising both
patient-centred and intervention-specific results.
Experts in the field have agreed that a COS would en-
hance the reliability of systematic reviews [12]. However,
a recently published systematic review [13] on available
COSs for comparative effectiveness research highlighted
that no COS exists for trials investigating pre-, intra- or
post-surgical interventions in conventional cardiac surgery
(elective and emergency non-minimally invasive off- or
on-pump procedures, excluding transplants).
Definitions of terms and key concepts described in this
study protocol follow those proposed by the OMERACT
initiative [9] and the Core Outcome Measures in Effective-
ness Trials (COMET) Initiative [8]. They are presented in
Table 2.
Aims and objectives
The aim of this study is to develop a COS relevant to all
types of cardiac surgery effectiveness trials. The specific
study objectives are to determine which outcome do-
mains should be measured in all clinical trials (what to
measure, the core domain set) and secondly, to define
measurement instruments for the outcome domains
(how to measure, the COS).
This does not imply that primary outcomes of cardio-
thoracic surgical trials should always and exclusively be
those of the COS. However, to ensure the comparability
of results across trials, the outcomes included in this
COS should be considered for inclusion besides measuring
trial-specific clinical endpoints.
Methods/design
The conduct and reporting of this COS adheres, as
much as is practicable, to the recommendations given by
the COMET Initiative [8] on the development of a mini-
mum COS in general, the methodological guidance pro-
vided by Sinha and colleagues [14] on the conduct and
reporting of Delphi studies and by the OMERACT Initia-
tive [9] on identifying outcome measurement instruments.
Ethical approval was obtained from the responsible
ethics committee of the Faculty of Medicine, RWTH
Aachen (EK 338/14).
Scope of this COS
This COS is intended for clinical trials measuring the ef-
fectiveness of pre-, intra- or post-surgical interventions
in non-minimally invasive off- or on-pump cardiothor-
acic surgery (elective and emergency procedures, ex-
cluding transplants, participants >18 years).
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Identification of existing knowledge
In preparation for this study, our group performed a
systematic review of reviews to evaluate current clinical
research on non-minimally invasive off- or on-pump
cardiothoracic surgery (elective and emergency surgeries,
excluding transplants and investigating pre-, intra- or
post-surgical interventions) to determine the type and
number of outcomes reported so far [4]. Pre-, intra- and
post-surgical interventions were defined as any interven-
tion related to the outcome of the procedure that occurred
before, during or after cardiac surgery. Furthermore, we
assessed to what extent outcomes in cardiothoracic surgi-
cal interventional trials were patient-centred and reflect pa-
tients’ perception, interpretation or evaluation of their
condition and quality of care. Special focus was laid on
endpoints that concentrated on salutogenesis, and 15
systematic reviews involving 371 randomised trials and
58,253 patients were included in our systematic review.
We established unique lists of salutogenically and non-
salutogenically focused outcomes, which collapsed into 38
outcome categories providing a list of potential core do-
mains for the proposed minimum COS.
Method to reach consensus on the core domain set
(what to measure)
The Delphi method is iterative and uses a series of rounds
of data collection and analysis to condense the opinions of
individuals into a group consensus. Typically, it involves
the use of sequential rounds of postal questionnaires that
are designed to elicit participants’ opinions on a particular
topic. Responses to each round are collated, analysed and
redistributed to participants for further comment in
successive rounds. Delphi surveys have been applied in
other COS research groups [14]. Sinha and colleagues
summarised key points, providing guidance on the
Delphi technique to reach consensus on a minimum
Fig. 1 Development of a COS
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COS. Additionally, a recommended checklist of report-
ing items supports the reporting of Delphi studies,
which we will adopt. Based on this, we decided to
conduct an eDelphi survey online, to facilitate inter-
national participation without the time lag between
successive rounds associated with traditional postal
surveys, to enable a relatively low cost structure, to
increase data collection efficiency and to provide the
potential for a higher response rate through rapid
communication with participants. The survey will be
conducted using the online survey software Question-
Pro (http://www.questionpro.com).
Table 2 Definitions of key concepts used in this study protocol (adapted from Boers et al. [9])
Key Concept Definition
Health condition A situation of impaired health
Health intervention An activity performed by, for, with or on behalf of a client(s) whose purpose
is to improve individual or population health, to alter or diagnose the course
of a health condition or to improve functioning
Core area An aspect of health or a health condition that needs to be measured to assess
appropriately the effects of a health intervention (core areas are broad concepts
consisting of a number of more specific concepts called domains)
Domain Component of core area: a concept to be measured, a further specification of an
aspect of health, categorised within a core area
Outcome Any identified result in a domain arising from exposure to a casual factor or a
health intervention
Measurement instrument A tool to measure a quality or quantity of a variable; in this context, a domain or
a contextual factor
Core domain set In the study of health interventions, the minimum set of domains and subdomains
necessary to cover adequately all core areas (fully measure all relevant concepts of
a specific health condition within a specified scope); it describes what to measure
Core outcome measurement set Definition introduced by the OMERACT Initiative
The minimum set of outcome measurement instruments that must be administered
in each intervention study of a certain health condition within a specified setting to
cover adequately a corresponding core domain set; it describes how to measure
Core outcome set Definition introduced by the COMET Initiative
The agreed minimum set of outcomes that should be measured and reported in all
clinical trials for a specific clinical area
Scope The set of factors that describe the studies and circumstances to which the COS will
apply; this is determined by the study questions and includes the health condition(s),
target population, interventions and so forth
Contextual factor A variable that is not an outcome of the study, but needs to be recognised
(and measured) to understand the study results; this includes potential confounders
and effect modifiers
Table 1 OMERACT Filter 2.0 framework: core areas to be considered for outcome measurement in health intervention studies
(adapted from Boers et al. [9])
Core area Specification
Death This core area includes possible specifications of death, such as generic or
disease-specific (all causes versus disease-specific mortality), and intervention-specific
(for example, death due to surgery).
Life impact This core area can include domains of the International Classification of Functioning,
Disability and Health (ICF) (such as activity and participation) and domains for
health-related quality of life (such as functional status, general health perceptions and
overall quality of life).
Resource use and economic impact This core area describes the economic impact of health conditions both on society and
on the individual. A health condition and its treatment incur resource use.
Pathophysiological manifestations This core area assesses whether the effect of the intervention specifically targets the
pathophysiology of the health condition. Pathophysiology can include psychosocial
manifestations. Example domains are ICF body function, reversible manifestations
(including modifiable risk factors and actual manifestations of ill health) and irreversible
manifestations (including unmodifiable risk factors and damage). This area can also
encompass all biomarkers and surrogate outcomes.
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It is intended to reach consensus on core outcome do-
mains (what to measure) in a three-round eDelphi exer-
cise. The first round will contain all outcome domains
identified by the aforesaid systematic review.
Stakeholder involvement
Participation is sought from people within the following
broad groups: adult patients in need of or after cardio-
thoracic surgery (any non-minimally invasive off- or
on-pump operational procedure on the adult heart),
cardiothoracic surgeons, cardiologists, anaesthesiolo-
gists, nursing staff involved with adult cardiothoracic
patients and researchers with expertise in this particu-
lar field of medical research. There is currently no
standard method for sample size calculations in Delphi
processes, and thus a broad approach is taken to ensure
there is sufficient and international participation in this
Delphi study.
An email inviting participation will be sent to the fol-
lowing groups identified as relevant to the broad area
of expertise regarding the subject under investigation:
the German Heart Foundation, the British Cardiac Pa-
tients Association, the European Heart Network, the
Support Network of the American Heart Association,
the German Society for Thoracic and Cardiovascular
Surgery (DGTHG), the European Association for
Cardio-Thoracic Surgery, the American Association for
Thoracic Surgery, the Society of Thoracic Surgeons, the
Cardiothoracic Surgery Network (CTSNet), the German
Society of Anaesthesiology and Intensive Care Medicine,
the European Society of Anaesthesiology, the American
Society of Anaesthesiologists and the Cochrane Heart
Group. The aim is to approach researchers with know-
ledge of performing a meta-analysis and in a developing
COS. Participants are then invited to use snowball sam-
pling by forwarding the invitation to colleagues whom
they regard as having the required expertise to contribute
substantially to this eDelphi survey and the development
of the COS. Those who participate will be asked to re-
spond with their name, country of origin and email ad-
dress. Prior to the eDelphi questions in round one,
informed consent will be obtained and participants will be
given information about the study and minimum COS.
Here, plain language summaries provided by the COMET
Initiative on COSs and the Delphi process in general will
be utilised. These will provide patient representatives and
professionals with the same information written in
language suitable for all involved stakeholders. In
addition, OMERACT Filter 2.0 (Table 2) will be pre-
sented to all participants highlighting especially the
four core areas (death, life impact, resource use and
pathophysiological manifestations), which should be
addressed by the domains of every COS. However, our
study group decided that we would not initially group
the outcome domains identified via the systematic re-
view according to the recommended core domains of
OMERACT Filter 2.0. Considering the most com-
monly assessed domains in previous studies (measures
of mortality, cerebrovascular complications and hospitalisa-
tion), we felt that such an approach would restrict the
course of the eDelphi unjustifiably and that we would pre-
judge the selection of outcome domains for the core set.
Participants will also be asked to provide information
on their educational and professional background, their
experience with clinical research relevant for cardiac sur-
gery and whether they were invited to participate as pa-
tients. Participants will be encouraged to complete the
eDelphi questionnaire in each round. Each round will
have a response closing date 28 days after the date of in-
vitation. Email reminders will be send to anyone who
did not respond by day 7 and after 2 weeks.
eDelphi round 1
In the eDelphi, the order of potential core domains
identified a priori via our systematic review of reviews
will be randomised before being shown to participants.
Based on the example given by Chiarotto et al. [15],
participants will be asked to indicate if a domain is im-
portant enough to be included as a core domain. Response
options will be: (a) “yes”, (b) “no” and (c) “unsure/I do not
know”. Participants will be encouraged to suggest modifi-
cations of definitions and the wording of the domains.
They will be asked to indicate if they consider that there is
a large conceptual overlap between some domains and to
judge whether some domains should be combined. Par-
ticipants will also be asked to identify up to two new
outcome domains, which they judge to be relevant or
important.
The responses of round one will then be analysed
using descriptive statistics. Frequencies on the import-
ance of domains will be calculated for the whole panel.
In addition, we will analyse responses from patient rep-
resentatives separately to assess if they contrast from the
general panel rating to ensure that their voice is heard.
Our study team established a priori that domains for
which at least 60 % of the participants choose the response
option “no” and less than 20 % choose the response option
“yes” will be dropped from the list of potential core do-
mains. Additional outcome domains identified by partici-
pants in round one will be included if suggested by at least
two participants.
eDelphi round 2
A feedback report will be provided to the panel mem-
bers before round 2 of the eDelphi. At this stage, the
study team will propose deleting all domains from the
list of potential core domains for which at least 60 % of
the participants chose the response option “no” and less
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than 20 % chose the response option “yes”. Secondly, the
study team will provide additional proposals based on
participants’ comments from round one concerning, for
example, the aggregation of other potential core do-
mains. Participants will be asked to re-rate them at this
point using their knowledge of their individual and the
group’s previous ratings and to indicate whether they
agree with the proposed decisions. The study team set
consensus at 67 % agreement (two-thirds majority). Sub-
sequently, participants will be asked to rate the newly
identified outcome domains from round one using the
same response options from round one: (a) “yes”, (b)
“no” and (c) “unsure/I do not know”.
Upon completion, responses from round two will be
analysed descriptively and summarised in a feedback re-
port. Again, responses from patients’ representatives will
be analysed separately to highlight deviations from the
rest of the panel.
eDelphi round three
In round three, participants who responded to round
two will be presented with the feedback report from
round two. Outcome domains retained after analysis of
responses from round two will be presented and panel
members will be asked if each outcome domain was in-
deed core. Response options will be the same as in the
first two rounds and participants will be given the op-
portunity to provide arguments for their choices. As in
round two, consensus will be set at 67 % for the panel to
agree on the core domains to be included in the core
domain set. If discrepancies arise or controversial ar-
guments continue, the results will be discussed in
depth within our study group, where the final decision
will be made.
Result of the eDelphi
The end result of the three-round eDelphi exercise will
be the core domain set for all clinical trials investigating
the effectiveness of pre-, intra- or post-surgical inter-
ventions in non-minimally invasive off- or on-pump
cardiothoracic surgery (elective and emergency proce-
dures, excluding transplants, participants >18 years). It
is intended that the identified core domains should at
best cover all four core areas (death, life impact, re-
source use and pathophysiological manifestations) of
OMERACT Filter 2.0 (Table 1).
Method to reach consensus on the COS (how to measure)
The final step in developing the anticipated COS will be
to decide how to measure the identified core domains.
For this step, we will follow the recommendations
given by the OMERACT Initiative as described in the
OMERACT Handbook [16]. The results of our systematic
review of reviews will at best provide a list of potential
measurement instruments; where no or no adequate list
of possible instruments is available, a literature review will
be performed to identify possible matching measurement
instruments for each of the agreed core domains. Where
only partially validated instruments are identified for the
setting of the domains, or where no instruments are
available in a domain, instruments will need to be fur-
ther validated, or respectively developed, and their ap-
plicability documented.
Where no instruments are available, these need to be
developed. For applicability, each instrument must prove
to be valid, discriminative and feasible [9]. When all core
domains can be measured by at least one applicable in-
strument, the end result is a draft that again is subjected
to a consensus procedure with all stakeholders, resulting
in the final COS.
Implementation and updating of this COS
The uptake and implementation of a COS also needs to
be carefully considered. An observational review [17] in
a different clinical field (rheumatoid arthritis) was car-
ried out to investigate whether there were trends in the
proportion of trials reporting on the full set of core
outcomes over time. The results suggest that a higher
percentage of trialists conducting trials in rheumatoid
arthritis are now measuring the rheumatoid arthritis
COS. Therefore, COSs have the potential to improve the
evidence base for a special clinical field, but consider-
ation must be given to the methods for disseminating
their availability amongst relevant stakeholders.
First and foremost, our COS is registered with the
COMET database (http://www.comet-initiative.org/studies/
details/630?result=true), which provides access to trialists
and researchers involved in this clinical area.
To increase COS uptake, it is recommended [8] that de-
velopers consider engagement with the relevant Cochrane
Review Groups, clinical guideline developers, research
funders, journal editors, regulators such as research ethics
committees, and trial registries. We intend to do so in
close cooperation with the COMET Initiative. In addition,
this COS and its development process will be introduced
at a COMET meeting and at least at one national and
international conference with a focus on cardiac surgery.
Reviewing a COS regularly is important as a form of
validation, to ensure outcomes are still important to all
stakeholders, to give the chance to add new outcomes,
to evaluate how successful implementation has been and
to engage further stakeholders if suitable [8]. The ques-
tion of who should review a COS in what timeframes
needs careful consideration. So far, no recommendations
exist. Our study group will revisit this issue regularly
and follow up on this topic within 2 years of the first
published version of the proposed COS.
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Discussion
There is currently no COS relevant for clinical trials meas-
uring the effectiveness of interventions in non-minimally
invasive off- or on-pump cardiothoracic surgery. The
proposed COS aims to improve cardiac interventional
research by limiting reporting bias and heterogeneity
across trials to ensure the comparability of effects and
synthesis of research results in the future. We will in-
volve multiple stakeholders and apply agreed qualitative
standards to ensure the applicability and dissemination
of the intended COS.
This research will benefit all stakeholders involved in
cardiac surgical management in Germany, Europe and
beyond. Researchers will be able to design clinical trials
and synthesise research evidence that takes those out-
comes under consideration that are important to all
stakeholders. Thus, clinicians will be better equipped to
facilitate informed decision-making by cardiac patients.
Trial status
The eDelphi study started in March 2015. We intend to
publish the results of the eDelphi, the core domain set,
in late 2015.
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